[cnbc 3000085212]
CNBC’s Herb Greenberg looks at why several analysts covering Mylan may have cut their first quarter earnings estimates within a few days of each other, citing concerns about the anti-depressant Lexapro. Herb’s question: ‘Did the company engage in some kind of selective disclosure?’
Melissa Lee anchors a fast-paced discussion among four professional Wall Street traders. An hour after the bell Fast Money hosts one of the best trading discussions of the day.
Video © and provided by CNBC.
Be the first to comment